rct
    2019
    High Quality

    L-theanine in the adjunctive treatment of generalized anxiety disorder: A double-blind, randomised, placebo-controlled trial

    Sarris J, Byrne GJ, Cribb L, Oliver G, Murphy J, Macdonald P, Nazareth S, Karamacoska D, Galea S, Short A, Ee C, Birling Y, Menon R, Ng CH

    Published in Journal of Psychiatric Research

    Methodology

    Ten-week double-blind, randomised, placebo-controlled adjunctive trial of L-theanine 450-900 mg/day in adults with generalised anxiety disorder on stable antidepressant therapy.

    Key Findings

    L-theanine did not outperform placebo on anxiety (HAMA) or insomnia severity, though it was well tolerated with no serious adverse events.

    Conclusions

    Adjunctive L-theanine did not reduce anxiety in generalised anxiety disorder.

    Limitations

    Modest sample size; adjunctive design in already-treated patients may mask effects.

    Supplements Studied

    L-Theanine
    Amino Acid

    L-theanine did not outperform placebo on anxiety or insomnia severity in generalised anxiety disorder.

    Related Health Concerns

    Study Details

    Year:2019
    Sample Size:46
    Duration:10 weeks
    Quality Score:9/10

    Disclosures

    Funding

    Australian academic funding with product supplied by manufacturer

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.